Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|May 4, 2012

Additional Imaging Recs in Oncologic PET/CT Reports Often Unnecessary

About half of additional imaging requests in oncologic PET/CT reports are unnecessary.

About half of additional imaging requests in oncologic PET/CT reports are unnecessary, said researchers from Brigham and Women’s Hospital in Boston. The results of their study were presented at the American Roentgen Ray Society Annual Meeting in Vancouver, Canada.

Radiologists and nuclear medicine physicians recommend additional imaging to confirm findings about 30 percent of the time. To assess the necessity of the additional scans, researchers looked at the records of 250 patients, 84 of whom had been recommended for additional imaging. Researchers found that 43 of the recommendations were not necessary and would not have affected patient outcome if they had not been done.

“We feel that some of the most important factors leading to unnecessary recommendations include reluctance of physicians to accept uncertainty regarding diagnosis, partly driven by medicolegal concerns, combined with a failure to fully consider the patients’ clinical circumstances and the likely cost-effectiveness of additional imaging tests,” said Atul Shinagure, MD, one of the study’s authors.

Referring physicians also did not follow through on the recommendations 70 percent of the time, the authors said. This may be because radiologists and nuclear medicine physicians might not have complete medical histories of patients referred for PET/CT imaging.

“Ordering clinicians usually know the patient record and history,” said Shinagare. “[This] may put them in a better position to judge the necessity of some recommended additional imaging.”
 

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.